The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Open accessAbstract
Summary Prostate cancer is characterized by its dependence on androgen receptor and frequent activation of PI3K signaling. We find that AR transcriptional output is decreased in human and murine tumors with PTEN deletion and that PI3K pathway inhibition activates AR signaling by relieving feedback inhibition of HER kinases. Similarly, AR inhibition activates AKT signaling by reducing levels of the AKT phosphatase PHLPP. Thus, these two oncogenic pathways cross-regulate each other by reciprocal feedback. Inhibition of one activates the other, thereby maintaining tumor cell survival. However, combined pharmacologic inhibition of PI3K and AR signaling caused near complete prostate cancer regressions in a Pten-deficient murine prostate cancer model and in human prostate cancer xenografts, indicating that both pathways coordinately support survival. Significance The two most frequently activated signaling pathways in prostate cancer are driven by AR and PI3K. Inhibitors of the PI3K pathway are in early clinical trials and AR inhibitors confer clinical responses in most patients. However, these inhibitors rarely induce tumor regression in preclinical models. Here we show that these pathways regulate each other by reciprocal negative feedback, such that inhibition of one activates the other. Therefore, tumor cells can adapt and survive when either single pathway is inhibited pharmacologically. Our demonstration of profound tumor regressions with combined pathway inhibition in preclinical prostate tumor models provides rationale for combination therapy in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citationCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Self-citationThoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Cited by
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Self-citationOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Self-citationTargeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Self-citationRebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Attard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
“Phosphatidylinositol 3-kinase (PI3K)/AKT signaling can influence the progression of CRPC and effectively compensate for reduced AR activity in PC models via reciprocal feedback activation (Carver et al., 2011; Mulholland et al., 2011).”
BackgroundIdentification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
Karthaus, W. R., Iaquinta, P. J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C. M., Gao, D., Begthel, H., Sachs, N., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.017 · Cited by 727
Self-citationLi, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Self-citationClinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Self-citationTewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 628
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Self-citationSandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
Polkinghorn, W. R., Parker, J. S., Lee, M. X., Kass, E. M., Spratt, D. E., Iaquinta, P. J., Arora, V. K., Yen, W.-F., Cai, L., Zheng, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0172 · Cited by 559
Self-citationN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Dardenne, E., Beltran, H., Benelli, M., Gayvert, K., Berger, A., Puca, L., Cyrta, J., Sboner, A., Noorzad, Z., MacDonald, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.005 · Cited by 559
Self-citationEffective combinatorial immunotherapy for castration-resistant prostate cancer
Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 547
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Tracking the clonal origin of lethal prostate cancer
Haffner, M. C., Mosbruger, T., Esopi, D. M., Fedor, H., Heaphy, C. M., Walker, D. A., Adejola, N., Gürel, M., Hicks, J., Meeker, A. K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70354 · Cited by 497
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Self-citationAndrogen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Menden, M. P., Wang, D., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T., Kang, J., Jeon, M., Wolfinger, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 363
Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt136 · Cited by 357
Single luminal epithelial progenitors can generate prostate organoids in culture
Chua, C. W., Shibata, M., Lei, M., Toivanen, R., Barlow, L. J., Bergren, S. K., Badani, K. K., McKiernan, J. M., Benson, M. C., Hibshoosh, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3047 · Cited by 351
Master Regulator Activating Transcription Factor 3 (ATF3) in Metabolic Homeostasis and Cancer
Ku, H.-C., & Cheng, C.-F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00556 · Cited by 345
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00580-8 · Cited by 335
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A., & de Bono, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 329
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Bitting, R. L., & Armstrong, A. J. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0394 · Cited by 311
de Bono, J. S., De Giorgi, U., Rodrigues, D. N., Massard, C., Bracarda, S., Font, A., Arranz Arija, J. A., Shih, K. C., Radavoi, G. D., Xu, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0981 · Cited by 311
Implementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
PSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Zadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., Syamala, S., Bango, C., Photopoulos, C., Huang, Y., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808834116 · Cited by 291
Karantanos, T., Evans, C. P., Tombal, B., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.049 · Cited by 285
Chen, Y., Chi, P., Rockowitz, S., Iaquinta, P. J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B. S., Wongvipat, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3216 · Cited by 282
Self-citationPI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
Isikbay, M., Otto, K., Kregel, S., Kach, J., Cai, Y., Vander Griend, D. J., Conzen, S. D., & Szmulewitz, R. Z. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0173-2 · Cited by 274
Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., Smas, M. E., Lord, J. B., Brannigan, B. W., Trautwein, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0222 · Cited by 272
Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.027 · Cited by 268
Okkenhaug, K., Graupera, M., & Vanhaesebroeck, B. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0716 · Cited by 264
Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer
Brocks, D., Assenov, Y., Minner, S., Bogatyrova, O., Simon, R., Koop, C., Oakes, C., Zucknick, M., Lipka, D. B., Weischenfeldt, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.053 · Cited by 260
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W., Linton, E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 259
Self-citationPowles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01600-6 · Cited by 256
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Nguyen, H. G., Yang, J. C., Kung, H.-J., Shi, X.-B., Tilki, D., Lara, P. N., DeVere White, R. W., Gao, A. C., & Evans, C. P. (2014) · Oncogene · doi:10.1038/onc.2014.25 · Cited by 212
Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204
Self-citationKlempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
Badrising, S., van der Noort, V., van Oort, I. M., van den Berg, H. P., Los, M., Hamberg, P., Coenen, J. L., van den Eertwegh, A. J. M., de Jong, I. J., Kerver, E. D., et al. (2014) · Cancer · doi:10.1002/cncr.28518 · Cited by 136
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis
Mukherjee, R., Vanaja, K. G., Boyer, J. A., Gadal, S., Solomon, H., Chandarlapaty, S., Levchenko, A., & Rosen, N. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.033 · Cited by 135
Self-citationUSP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
HER3 Is an Actionable Target in Advanced Prostate Cancer
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68
Fizazi, K., Clarke, N. W., De Santis, M., Uemura, H., Fay, A. P., Karadurmus, N., Kwiatkowski, M., Alvarez-Fernandez, C., Jiang, S., Sotelo, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.004 · Cited by 55
Joshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
Yan, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., Ma, L., Chen, J., Yu, Z., He, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708478 · Cited by 53
Self-citationWen, S., Shang, Z., Zhu, S., Chang, C., & Niu, Y. (2013) · The Prostate · doi:10.1002/pros.22676 · Cited by 32
Kaittanis, C., Bolaender, A., Yoo, B., Shah, N., Ouerfelli, O., & Grimm, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b04209 · Cited by 19
Metadata
- Authors
- Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., Scardino, P. T., Rosen, N., & Sawyers, C. L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 19
- Issue
- 5
- Pages
- 575-586
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2073100248
- Cited by
- 1,198
- References
- 45
- FWCI
- 81.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.